Weight Gain in Cancer Patients Treated with Brain Penetrant RET-selective Inhibitors

The development of RET-selective inhibitors has recently revolutionized the treatment of cancers that have undergone this modification. While genetically modified RET kinases drive oncogenesis, GDF15 activates a wildtype form of the receptor by binding to the GFRAL receptor, which is found in the hindbrain’s appetite control centers. It has been preclinically demonstrated that the GDF15 / GFRAL / RET axis controls anorexia and cachexia, which lead to weight loss. In this study, which was conducted as part of clinical trials at the University of Texas MD Anderson Cancer Center, we examined trends in weight gain as a potential adverse event in patients receiving the CNS-permeable RET-selpercatinib and pralsetinim inhibitors.

Published
Categorized as Oncology

Leave a Reply